global glp-1 obesity drug market size forecast 2030 Goldman Sachs raises forecast: Oral enters mass market, projected to reach $114 billion by Anti-Obesity Drugs Market Size &
Description
We want you to feel heard, understood, and confident
Common side effects and how to manage them The most common side effects are gastrointestinal in nature, such as nausea, vomiting, diarrhea and constipation
Many people have started turning to GLP-1 drugs to help them lose weight
A programme of phase 3 trials with retatrutide (TRIUMPH) is ongoing with an aim to assess the safety and efficacy of retatrutide in different populations living with obesity (OSA, T2D, established cardiovascular disease, osteoarthritis)
